211 related articles for article (PubMed ID: 27635472)
21. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
22. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.
Ruzinova MB; Caron T; Rodig SJ
Am J Surg Pathol; 2010 Jun; 34(6):882-91. PubMed ID: 20442643
[TBL] [Abstract][Full Text] [Related]
23. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma.
Smith SM; Anastasi J; Cohen KS; Godley LA
Blood Cells Mol Dis; 2010 Dec; 45(4):317-23. PubMed ID: 20817505
[TBL] [Abstract][Full Text] [Related]
24. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
25. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
Fest T; Guffei A; Williams G; Silva S; Mai S
Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
[TBL] [Abstract][Full Text] [Related]
26. Bim is a suppressor of Myc-induced mouse B cell leukemia.
Egle A; Harris AW; Bouillet P; Cory S
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6164-9. PubMed ID: 15079075
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Sheth A; Escobar-Alvarez S; Gardner J; Ran L; Heaney ML; Scheinberg DA
Cell Death Dis; 2014 Mar; 5(3):e1152. PubMed ID: 24675470
[TBL] [Abstract][Full Text] [Related]
28. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
30. Impact of MYC on malignant behavior.
Ott G
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):100-6. PubMed ID: 25696841
[TBL] [Abstract][Full Text] [Related]
31. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
32. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
33. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
34. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.
Gan L; Xiu R; Ren P; Yue M; Su H; Guo G; Xiao D; Yu J; Jiang H; Liu H; Hu G; Qing G
Oncogene; 2016 Jun; 35(23):3037-48. PubMed ID: 26434591
[TBL] [Abstract][Full Text] [Related]
35. Reducing VDAC1 expression induces a non-apoptotic role for pro-apoptotic proteins in cancer cell differentiation.
Arif T; Krelin Y; Shoshan-Barmatz V
Biochim Biophys Acta; 2016 Aug; 1857(8):1228-1242. PubMed ID: 27080741
[TBL] [Abstract][Full Text] [Related]
36. MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
Kluk MJ; Ho C; Yu H; Chen BJ; Neuberg DS; Dal Cin P; Woda BA; Pinkus GS; Rodig SJ
Am J Clin Pathol; 2016 Feb; 145(2):166-79. PubMed ID: 26834124
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel Myc target genes with a potential role in lymphomagenesis.
Marinkovic D; Marinkovic T; Kokai E; Barth T; Möller P; Wirth T
Nucleic Acids Res; 2004; 32(18):5368-78. PubMed ID: 15477387
[TBL] [Abstract][Full Text] [Related]
38. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
[TBL] [Abstract][Full Text] [Related]
39. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
[TBL] [Abstract][Full Text] [Related]
40. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.
Aoki T; Shimada K; Sakamoto A; Sugimoto K; Morishita T; Kojima Y; Shimada S; Kato S; Iriyama C; Kuno S; Harada Y; Tomita A; Hayakawa F; Kiyoi H
Oncotarget; 2017 Feb; 8(8):13085-13098. PubMed ID: 28055963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
